NHS Branded Medicines Tranche Framework for London and South of England
A Contract Award Notice
by NHS ENGLAND
- Source
- Contracts Finder
- Type
- Contract (Products)
- Duration
- 2 year
- Value
- £381M
- Sector
- HEALTH
- Published
- 20 Aug 2024
- Delivery
- 01 Sep 2024 to 31 Aug 2026
- Deadline
- 05 Apr 2024 12:00
Concepts
Location
1 buyer
- NHS England Runcorn
29 suppliers
- Sun Pharma Hillingdon
- Biogen Maidenhead
- Merck Sharpe & Dohme London
- Celltrion Healthcare Slough
- Astrazeneca London
- Janssen Cilag High Wycombe
- Organon Pharmaceuticals London
- Thornton & Ross Huddersfield
- Glaxosmithkline Great West Road Brentford
- Takeda Kingdom Street London
- Pfizer Tadworth
- Novartis Pharmaceuticals London
- Zentiva Pharma Guildford
- Roche Products Welwyn Garden City
- Eli Lilly Basingstoke
- Aventis Pharma Reading
- Accord Whiddon Valley Barnstaple
- Orifarm Brentwood
- Galapagos Biotech Uxbridge
- Manx Healthcare Warwick
- Chugai Pharma Turnham Green London
- Napp Pharmaceuticals Cambridge
- Drreddys Laboratories Cambridge
- Leo Pharma Maidenhead
- Gedeon Richter Westminster
- Biosimilar Collaborations Ireland London
- Sobi Swedish Orphan Biovitrum Great Abington
- Teva Glasshoughton Castleford
- Ucb Pharma Slough
Description
NHS Branded Medicines Tranche Framework for London and South of England - 1 September 2024 Offer reference number: CM/PHR/22/5689 CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South of England Tranche A. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South of England Tranche B. Period of framework: 1 September 2024 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/03 - NHS Framework for the supply of Omalizumab and Diroximel Fumarate for the Midlands & East and North of England. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.
Award Detail
1 | Sun Pharma (None)
|
2 | Biogen (Maidenhead)
|
3 | Merck Sharpe & Dohme (London)
|
4 | Celltrion Healthcare (Slough)
|
5 | Astrazeneca (London)
|
6 | Janssen Cilag (High Wycombe)
|
7 | Organon Pharmaceuticals (London)
|
8 | Thornton & Ross (Huddersfield)
|
9 | Glaxosmithkline (Great West Road Brentford)
|
10 | Takeda (Kingdom Street London)
|
11 | Pfizer (Tadworth)
|
12 | Novartis Pharmaceuticals (London)
|
13 | Zentiva Pharma (Guildford)
|
14 | Roche Products (Welwyn Garden City)
|
15 | Eli Lilly (Basingstoke)
|
16 | Aventis Pharma (Reading)
|
17 | Accord (Whiddon Valley Barnstaple)
|
18 | Orifarm (None)
|
19 | Galapagos Biotech (Uxbridge)
|
20 | Manx Healthcare (Warwick)
|
21 | Chugai Pharma (Turnham Green London)
|
22 | Napp Pharmaceuticals (Cambridge)
|
23 | Drreddys Laboratories (Cambridge)
|
24 | Leo Pharma (Maidenhead)
|
25 | Gedeon Richter (None)
|
26 | Biosimilar Collaborations Ireland (London)
|
27 | Sobi Swedish Orphan Biovitrum (Great Abington)
|
28 | Teva (Glasshoughton Castleford)
|
29 | Ucb Pharma (Slough)
|
CPV Codes
- 33600000 - Pharmaceutical products
Indicators
- Contract is suitable for SMEs.
Other Information
Transparency Award Schedules - London & South of England - CM_PHR_225689_02 Transparency Award Schedules - London & South of England - CM_PHR_225689_02.pdf Transparency Award Schedules - London & South of England - CM_PHR_225689_01 Transparency Award Schedules - London & South of England - CM_PHR_225689_01.pdf Transparency Award Schedules - Omalizumab and Diroximel Fumarate for MAE & NOFE - CM_PHR_225689_03 Transparency Award Schedules - Omalizumab and Diroximel Fumarate for MAE & NOFE - CM_PHR_225689_03.pdf Parties Appointed to Framework Agreement -CM_PHR_22_5689 - London & South of England - 1st September 2024 Parties Appointed to Framework Agreement -CM_PHR_22_5689 - London & South of England - 1st September 2024.doc Framework Agreement and Terms and Conditions - CM_PHR_22_5689 - London & South of England - 1st September 2024 Framework Agreement and Terms and Conditions - CM_PHR_22_5689 - London & South of England - 1st September 2024.pdf
Reference
- CF-2545400D0O000000rwimUAA
- CF 5804a973-6494-40b3-8ef1-7809f1927694